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The topic of this thesis is about using investment funds to support advancements in 
healthcare. The structure is designed to identify the relevant elements in a funding strategy 
that can be used to support healthcare companies likely to produce usable solutions. 
 
The research objective is to establish a proper investment fund strategy that supports 
healthcare. Additionally, it is positioned to highlight the dynamic components that outline 
the viable fund.  
 
The preliminary scope of the literary review considered the following elements to be rele-
vant subjects for evaluation on: current healthcare funding and challenges, successful funds 
both inside and outside the health sector, various fund types, strategies, approaches, and 
structure possibilities within the mutual fund and hedge fund industry.  
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 INTRODUCTION 
 Background 
The topic of this research is regarding effective, relevant Investment- funding strategies 
that enable a positive impact on the healthcare sector alongside generating a financial 
return.  It is motivated by the never-ending challenges associated with human healthcare, 
and the assistance that investment- funded vehicles can provide. Due to the practical aim 
of this study; the research context assumes a prescriptive model. The research objective 
is to establish a suitable investment fund strategy that supports healthcare companies. 
Additionally, it is positioned to highlight the components that are most likely to support 
prominent healthcare companies. 
 
To provide a macro context by which the theoretical framework is based on; The author 
explains the concomitant relationships between relevant themes in the study: The ele-
ments of the framework central to the thesis include: Investment funding, Healthcare 
goals, Scientific achievement, technology, free enterprise, and investor behavior.  
 
The idea of funding by investment allows investors with a common interest to pool re-
sources together, usually under professional management & supervision. The built-in ad-
vantages of investment funds include economies of scale, risk management, asset diver-
sification, and a wide selection of investment opportunities. Investment funds are becom-
ing increasingly large and powerful. Investment funds have a unique ability to furnish 
almost any endeavor and serve as a catalyst for business activities in the long or short 
term. According to the 2015 Investment Company Fact Book: In the year 2014, U.S. 
Mutual funds held an estimated 18.2 Trillion, while worldwide holdings amounted to ap-
proximately 33.4 Trillion. At the end of 2014, investment funds accounted for 24% of 
household financial assets.  Historical growth of the percentage of shares held by invest-
ment companies over the past decades can be seen in the figure below. 
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Figure 1. Percentage of household financial assets held by investment 
companies; year 1980–2014. (Investment Company Institute, 2015) 
 
For individuals, about half their assets in 401(k) and similar plans or retirement accounts 
were invested in mutual funds alone. Funds have seen tremendous growth in both popu-
larity and utility because they allow a wide range of actors to benefit from their customi-
zable structure and inherent potentials. (Investment Company Institute, 2015) 
 
Improvements in healthcare research and treatment solutions have long been a collective 
effort supported by institutions and the leadership in most societies. The societal burden 
imposed by diseases not only affects the quality and quantity of human life; they also 
have a considerable strain on economic efficiency. U.S healthcare costs account for 
17.5% of the total GDP with an average cost of $9,523 per person (Martin et al., 2015. 
150-160). In the United States, two diseases account for approximately half of all deaths, 
heart disease, and cancer. (Nichols, 2015). In 2012, a group of medical researchers set out 
to examine sustainability in healthcare funding. The study was conducted to compare the 
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funding of cancer research with the actual burden imposed by each type of cancer. The 
results showed considerable inconsistencies in research funding levels when compared to 
the societal burden. The study contended that the allocation of funds should appropriately 
match the societal burden. (Carter, 2015)  
 
Researching and developing solutions to prevent and treat diseases typically originate in 
the science/research lab. Scientists, medical researchers often face funding challenges due 
to the complex nature of producing useable discovery. Producing results (Treatments, 
drugs) in medical R&D is costly, risky by nature and often requires significant additional 
funding to make it to commercialization. Companies with secure intellectual property and 
a clear business plan, a track record of repeated innovation, and a strong management 
team represent the ideal biotechnology firm.  
 
Almost all the recent progress made in healthcare with regards to enhancing quality and 
quantity of human life has been made possible with the help of Science. Impactful break-
throughs that enhance our understanding the world often begin with scientific discovery. 
Researchers from the University of California Berkley emphasized the relationship be-
tween science and technology as: "Science and technology feed off one another, 
propelling both forward. Scientific knowledge allows us to build new technologies, which 
often allow us to make new observations about the world, which, in turn, allow us to build 
even more scientific knowledge, which then inspires another technology … and so 
on."(Understanding Science, 2016) 
 
When it comes to revolutionizing the world in which we live, technology has proven to 
be an indispensable tool. The current upwards trend of technological achievement is un-
precedented. Just as the advent of physical tools propelled human development. The gains 
in technology represent a new set of tools being made available for public use. These 
tools represent an extension of human ability that can not only solve today's problems but 
enable future solutions. 
 
Private enterprises around the world are building these tools with unmatched efficiency 
and utility. Just as science inspires technological innovation, the application of that tech-
nology is by in large made possible by profitable companies. Companies motivated by 
profit tend to improve on that technology and rely on mass adoption to reduce the cost of 
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the technology itself. This effectively supplements the environment with an extra layer of 
support. Now the environment contains two tools that complement each other and has 
incorporated capitalism as the driving force. Industries like biotechnology are the product 
of blending the abilities of technology and science.   
 
The unique aspect to consider is how incentives play a role in this new environment. 
Improvements in human health require scientific discovery. Technology enables and 
stimulates scientific discovery, and knowledge in science promotes the development of 
technological solutions. Private enterprises amplify these solutions by maximizing their 
utility and distribution, thereby lowering the costs and risks associated with innovation. 
The evidence suggests that significant advancements in human health are greatly 
supplemented when the incentives of private enterprise intersect with the objectives of 
philanthropic and charitable actors. The convergence of incentives implies the maximi-
zation of participation and resource allocation by leveraging and combining existing be-
haviors across the spectrum. 
 
The last element to set the motivation by which the study begins the investigation is the 
underlying mechanisms that unite investors with healthcare advancement. For the 
healthcare companies to produce usable solutions, access to massive capital markets is 
paramount. Investment funds have certainly proved to be a valuable tool in connecting 
people with ideas, and have evolved significantly well over the past few decades. They 
are sophisticated enough to accommodate intangible assets alongside tangible financial 
instruments making them uniquely powerful tools. Investing is typically motivated by 
financial return. However, the idea of impactful investing has gained popularity in recent 
years. "Impact investing" is an emerging asset class that aims to amplify social benefits 
as well as generates financial returns. It is a permutation of Socially Responsible Investing 
designed to blend the values of philanthropy and traditional investing. Given the chal-
lenges being faced, investment funds certainly hold massive potential to impact the 
healthcare sector in a positive way; the question then becomes how. 
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 Research Aim 
The purpose of the research is to establish the applicable elements with regards to invest-
ment funding and how they might support health care companies likely to produce useful 
solutions. Upon analyzing the relationship between funding and healthcare; the research 
aim is then to identify the methods and strategies that can be used to leverage and align 
the goals of investors to increase participation and resources towards healthcare initia-
tives. 
 
The research will explore leading funding arrangements by merit of potential to influence. 
The research is also designed to assess the existing ecosystem for undercapitalized op-
portunities and to take it a step further by proposing a viable solution strategy. The chosen 
elements of the research are explored and discussed so that they may be used by anyone 
who wishes to set up a such a fund. The demand for healthcare improvements is perpetual 
in nature, and universal issue shared by all. The challenges that face the healthcare sector 
are without question some of the most challenging and resource-intensive to solve. This 
study is predicated on the notion that for-profit businesses are the foremost drivers of 
healthcare advancement and thereby aims to strengthen these drivers by appropriately 
leveraging financial resource tactics.  
 
 Research Questions 
1. How can investment funding support the healthcare companies that are likely to pro-
duce useful solutions? 
2. What are some effective investment fund structures, methods, and strategies that might 
attract the most capital towards healthcare? 
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 RESEARCH DESIGN 
 Method  
The purpose of this section is to provide explanations regarding the methods used in the 
research. This includes the method of data collection, the interpretation of that data, and 
how the data is applied.  
 
The adopted methodology for this study is largely driven by the aim of the research. The 
aim of the research is fulfilled when the research questions are addressed in that they 
propose and validate strategic funding policy. The style of questioning usually falls under 
one or more of the five research paradigms. 
 
The five types of research paradigms are:  
 Descriptive  
 Evaluative  
 Predictive 
 Exploratory 
 Prescriptive 
 
These paradigms influence the scope and method by which data is collected, analyzed, 
and applied throughout the research.  
 
The line of questioning in this particular study involves two separate styles of research, 
evaluative and prescriptive.  Since the aim is to evaluate leading funding arrangements 
while adhering to certain requirements, nature can be considered evaluative. After the 
evaluation, the prescription approach is used and goes beyond the first approach by as-
serting a potential solution to the problem. The prescriptive method framework implies a 
collection of strategies to administer. Before recommending a solution, the study gathered 
relevant information to be evaluated. This information is outlined in the literary review 
and can be seen as the ingredients necessary to deliver a prescription.   
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The secondary research is structured and explained historically as to how various fund 
structures appropriately serve different objectives throughout time. In the literature re-
view, there will be an overview of investment funds to inform the reader of what invest-
ment funds are capable of with the underlying theme of how, why, and when they are 
useful. The following chapter to this section is meant to research deeper to explain the 
origins, regulatory setting, and to assess the various types of mutual funds, as they are a 
core element of exploration. Hedge funds are also a topic of interest for their unique abil-
ity to leverage, hedge, and manage capital with less regulatory oversight. 
 
The relevant information is then compiled by the author to answer the research questions 
and fulfill the research aim. The relevant elements for evaluation include funding types, 
existing successful investment funds within healthcare, regulatory landscapes, favorable 
companies to fund, as well as the investment approach. Additional topics of interest 
include the current overview of modern day investment funding, impact ability, strategies, 
and approaches to attract significant amounts of capital. Investigating the criterion and 
method by which promising companies are incorporated in the portfolio is also a key 
element.  
 
One unstructured Interview took place with an experienced asset manager for the purpose 
of gathering general overview regarding optimal practices, jurisdictional advantages, in-
vestor relations, the interview assisted in narrowing the focus and scope of the literature 
review. The discussion briefly touched on the requirements by which institutional inves-
tors may engage with a fund, as well as the legal framework of soliciting, marketing se-
curities to institutions and other investors. The potential to incorporate Individual retire-
ment accounts as well as collective pension plans was also discussed. 
 
After analyzing the investment fund landscape, the researcher shifts focus to how the 
previous assessments relate to Investment regarding healthcare impact. After the initial 
description and introduction of the topic of healthcare, the research aims to highlight the 
potential for developments in healthcare investing, bearing in mind the prominent role 
companies play in the strategy of an investment fund. Specifically designed to shed light 
on effective strategies that address current challenges being faced. The next point in the 
paper will then be to propose the conditions and context of the appropriate fund and to 
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provide a dynamically appropriate strategy. The last chapter incorporates a tone of dis-
cussion in which the author provides conjecture to the study bearing in mind the complex 
orientation by which the study commenced.  
 Demarcation 
The scope of this paper is to examination investment fund vehicles that can provide a 
viable platform to fund healthcare advancements. The evaluation of existing literature 
will support the research aim and will be evaluated to confirm inquiries as to how they 
support health care achievements. Upon exploring relevant and beneficial elements in 
fund structures/strategies, the chosen elements are then carefully considered in addressing 
the research questions. This includes synthesis of various strategies to approach investing 
and to address application potential and limiting components. The synthesis is intended 
to produce a viable (fund) method while elaborating on the core components included. In 
the literary search for viable funding methods, the research is limited to two main fund 
verticals: Hedge Funds, and Mutual funds. The research collected regarding the legal 
framework, marketing methods, and general investment undertaking assumes the United 
States as the primary setting. The research is secondarily targeted to the end of enhancing 
the health span, lifespan, and life expectancy of the investor. Therefore, the strategy of 
the viable fund is to be one that includes investing in companies of different focus such 
as pharmaceuticals, biotechnology, personalized medicine and businesses from various 
sectors that directly or indirectly support healthcare advancement.  
 Abbreviations & Definitions 
IPO       Initial Public Offering 
FDA      Food and Drug Administration 
IP       Intellectual Property 
VC       Venture Capital 
R&D       Research and Development 
SEC      Securities and Exchange Commission 
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 LITERATURE REVIEW 
 Investment Fund Overview 
The concept of pooling financial resources to facilitate business, minimize risk, and yield 
investor returns has existed for a long time. Undertaking collective investments in trans-
ferable securities were first used in 18th century Holland preceding a financial crisis. In-
tentions were to minimize financial risk of government bond acquisition by encouraging 
participation from smaller investors (Vanderbyl and Kobelak, 2007). In recent decades 
Investment funds have received major attention; especially in the 1980's & 90's when they 
produced record high returns for investors across the globe. Scalability, leveraging, and 
diversification under professional management are conceptually some of the most pow-
erful tools, which intensify with collective effort. These concepts represent the core ele-
ments that make investment funded vehicles powerful.   
 
The desired outcome of an investment fund is typically classified by capital growth or 
value (income) growth. Investment funds tend to serve either a single asset class or a 
mixture of asset categories. Risk-reward profiles vary by asset class; The main asset class 
categories include: 
  
 Equities (Stocks),  
 Fixed income (Bonds) 
 Commodities 
 Real Estate  
 Cash equivalents (Money market instruments).  
 
 
 
 
 
 
 
10 
Depicted in figure 2 below; Equity funds accounted for the majority of all net assets 
within mutual funds in the year 2014, making it the most popular asset type.  
 
Figure 2. Equity funds held 52% of total mutual fund assets in 2014. (Investment 
Company Institute, 2015) 
 Mutual Funds in General 
The mutual fund industry is comprised of professionally managed investment companies 
that undertake investments from the public as well as institutions who are willing to invest 
in the purchase, sale or trade of securities. The mutual fund was started to enable com-
moners with limited means to participate in owning a portion of the market. The people 
did not have to spend much time practicing due diligence; rather they were sold a dream, 
a dream that could potentially result in financial freedom.  
 
Modern mutual funds in the United States are believed to have started after the creation 
of the Massachusetts Investors Trust in Boston in the year 1924, eventually going public 
in 1928. By 1929 The U.S. had more than nineteen open-ended mutual funds and approx-
imately seven hundred closed-end mutual funds. The stock market crash of 1929 
devastated the industry and wiped out most of the closed end mutual funds, but most the 
open end mutual funds were able to survive the collapse.   
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Mutual funds started to grow at an alarming rate and in the 1950s; there were more than 
one hundred mutual funds in the United States alone. The bull markets which occurred in 
the 1980s, and 1990s, also enabled the mutual funds to grow, even more, eventually 
reaching over three thousand in the United States. Total assets of mutual funds were es-
timated to be over one trillion US dollars in this period. The government began to put 
more corrective measures to regulate mutual funds following the mutual fund's scandal 
that occurred in the early 2000's. Despite these measures, mutual funds continued to grow 
at an accelerated rate. In the year 2006, there were estimated to be more than eight thou-
sand mutual funds in the United States with new markets opening in countries all over 
the world. The total assets of the more than eight thousand mutual funds in the United 
States were estimated to be approximately ten trillion us dollars. The figure below shows 
the historical growth of various types of mutual funds throughout time. 
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Figure 3. Number of Investment companies by type 1997-2014. (Investment Company 
Institute, 2015) 
 
The mutual fund has become more and more relevant in day to day life due to the signif-
icant role they play in household financial planning and retirement. The mutual fund in-
dustry is also important because it provides the investors with a convenient form of in-
vesting under professional management while offering diversification and liquidity. They 
were initially seen as an obscure financial instrument, but have since grown to become 
economically and personally essential. It is estimated that more than eighty million people 
in the United States invest in mutual funds, making it a critical component of the U.S. 
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economy. The American people have invested billions of dollars in the mutual fund in-
dustry, and many families' livelihood depends on the success of mutual funds (Investment 
Company Institute, 2016).  
 Authority over Mutual Funds 
Mutual funds in the United States are under the jurisdiction of the federal government 
and must be registered with the United States Securities and Exchange Commission. The 
Investment Company Act of 1940 is the legislation that governs the operations, structure, 
and rules for mutual fund investment companies. The act requires that any investment 
company with more than one hundred investors register and be subject to full disclosures 
of investment activity, board member duties, and most other day to day activities.  
 
The Securities and Exchange Commission was created to regulate the mutual funds 
among other investments offered to the public to safeguard the average citizen willing to 
invest in them. The United States government passed a Securities Act in the year 1934 
that regulated the sale and purchase of all securities, and the advisors who brokered the 
transactions. The SEC continues to be the governing force that checks the ecosystem for 
potentially fraudulent or dangerous activity as well as the entity that enforces legislation 
with regards to investment companies (Investment Company Institute, 2016).  
 Types of Mutual Fund Structures 
There are three main types of mutual funds in the United States are open-end funds, close-
end funds, and unit investment trusts. The open-end mutual fund is the most common 
mainly because they can buy back shares from investors daily. They are also the most 
common due to accessibility; open-ended funds are available for purchase either directly 
with the fund or indirectly through sales agents. Most open-end funds sell shares to the 
public daily. Purchasing and selling securities, however, fall under the purview of the 
fund manager. The number of shares that can be issued is technically without limit, and 
the number varies and is largely dependent on the share purchases, share redemptions as 
well as fluctuations in market price (Haslem, 2015).   
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The closed end mutual funds on the other hand only offer shares to the public at the point 
in time when they are formed. The closed end mutual funds are formed through an initial 
public offering, and only then are they listed on the stock exchange for interested 
members of the public. However, once the investors purchase the shares, they do not have 
the option to resell them back to the fund. This is a key factor that distinguishes open and 
closed ended mutual funds. 
 
In a closed end mutual fund, investors can only sell their shares to other investors who 
may be interested in buying. The price at which they sell to the other investors may also 
vary depending on the market situation. It may be lower or higher than the net asset value. 
When it is greater than the net asset value, it is said to be at a premium; accounting for 
the specific costs associated with that transaction. However, these shares are usually sold 
at a discount that is lower than the net asset value. Making it an attractive investment 
opportunity for other investors. The buying and selling of shares within a closed end mu-
tual fund are regulated by a professional investment manager whose job it is to ensure 
that the trades are carried out appropriately.  
 
The other type of the mutual funds is called unit investment trusts. Like the closed-end 
mutual fund, they can only issue their shares and securities once, and that is when they 
are created. However, unlike any of the other mutual funds, the unit investment trust has 
a limited life span that is set once it has been created. The portfolio of a unit investment 
trust is usually represented by a trustee or service provider and does not necessarily re-
quire active management. They have one similarity to the open end mutual funds in that 
the investor shares are redeemable at any time after the purchase or they can wait until 
the point of maturity when the unit investment trust will complete.  
 
The unit investment trust mutual funds also have another unique characteristic in that they 
have the ability to sell their shares in the open market. There are an estimated six-thou-
sand-unit investment trust mutual funds in the United States with an approximate value 
of assets that amount to over one hundred billion dollars. (Haslem, 2015)  
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 Hedge Funds in General 
Hedging risk has been a widely-used concept by investors through the years. The phrase 
"hedge fund" can be traced back to 1949. At that time, most investors opted for long-term 
market positions which prompted Alfred Winslow Jones to write an article pointing to 
the fact that investments could yield a higher return if hedging were to be applied to their 
investment techniques. To prove his hypothesis, Jones entered into an investment part-
nership and integrated short selling and leverage into his technique. The objective of im-
plementing the two was to increase the returns while at the same time lower the risks 
involved. By doing this Jones was able to establish two fundamental features that are still 
widely acknowledged and used. To achieve this, Jones applied an incentive of 20 percent 
and personally invested his money into the fund. He did this to demonstrate that his per-
sonal goals were aligned with the investors. 
 
Through his approach, Jones managed to achieve outstanding results. Between 1962 and 
1966, Joneses approach surpassed other funds by more than eighty-five percent. His 
twenty percent incentive fee allowed these individuals to earn as much as ten to twenty-
fold compared to the little they earned from "long-only" money managing services. 
Joneses dynamic and unique approach saw the launching of over a hundred and forty 
hedge funds in the following two years. This earned Jones, the title ‘the father of the 
hedge fund industry.' (Ineichen, 2002)  
 Hedge Fund Strategies 
Each hedge fund applies its unique strategy to differentiate from the others. However, 
most of these strategies can be grouped together in categories designed to assist a potential 
investor to make decisions on which hedge fund to invest in. Hedge fund strategies are 
typically categorized into four major categories namely: global macro, event-driven, di-
rectional and relative value (arbitrage). A fund manager may decide to employ more than 
one strategy to allow for more flexibility, better risk management as well as to extend 
diversification. 
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Global macro: Hedge funds that implement this strategy usually invest in shares, bonds 
and currency markets. This type of strategy anticipates the occurrence of various macro-
economic events that will generate a risk-adjusted return on their investments. Hence 
hedge fund managers must analyze global market incidences and trends to recognize the 
opportunities that these events provide. This type of strategy anticipates that the invest-
ment will attract good returns from the projected price shifts (Hedge Fund Basics - Man-
aged Funds Association, 2017). One important factor when using this type of strategy is 
to ensure proper timing as to guarantee high risk-adjusted returns. The global macro strat-
egy can be classified into either discretionary or systematic. Discretionary trading is 
whereby the fund manager identifies and chooses various investments that the fund will 
invest in. Systematic trading involves the usage of mathematical models to find the best 
investments to trade in. Software executes these mathematical models with little human 
engagement. Also, this kind of strategy can earn profits by following a trend or countering 
a trend by anticipating profit events from trend reversals. 
 
Event-Driven: This type of strategy involves situations where the investment opportunity 
or risk is associated with a certain event. This kind of strategy traces investment opportu-
nities in events such as acquisitions, consolidations, bankruptcies, and liquidations. Man-
agers who rely on this strategy must put much emphasis on valuation irregularities in the 
before and after the occurrence of such corporate oriented events. These corporate ori-
ented events are usually categorized into three classes which include distressed securities, 
risk arbitrage, and special situations. Distressed securities involve incidences like restruc-
turing and bankruptcies. Hence, it includes investing in bonds, loans or companies that 
are going bankrupt or are experiencing financial issues. 
 
Risk arbitrage is used where mergers, acquisitions, and liquidations are taking place 
(Hedge Fund Basics - Managed Funds Association, 2017). This involves trading the 
stocks of two or more firms that are merging to benefit from discrepancies that arise be-
cause of irregularities between the acquisition and stock price. However, this type of strat-
egy can backfire if the merger fails to go as planned. The last classification is with regards 
to special situations where certain occurrences like restructuring may influence the value 
of a firm. This may also occur when spin-offs, security issuance/repurchase, and asset 
sales take place. For hedge fund managers to take advantage of such events, they must 
identify them before they occur. A good manager using this type of strategy must be able 
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to determine events that will negatively or positively affect the value of a company and 
invest in it. 
 
Directional: The directional investment strategy relies on market shifts and deviations 
when choosing stocks from a given market. To choose the best possible stocks, computer 
models can be applied, or fund managers can personally search for and choose invest-
ments. This type of strategy offers more exposure to variations across an entire market, 
especially when compared to other market impartial approaches. If a fund manager has 
conviction about the direction of a market, he or she may use this method to investing in 
specific sectors such as technology, healthcare, biotechnology, and energy. The direc-
tional hedge fund strategy is often used by U.S and international long and short equity 
hedge funds. This is whereby long equity options are hedged by using short sales of eq-
uities (Hedge Fund Basics - Managed Funds Association, 2017).  
 Hedge Fund Structures & Overview 
Hedge funds can be based on a variety of structures that make each of them unique as to 
the method by which the fund achieves its goals; which is outlined the fund's private 
placement memorandum. Different hedge funds have different investment strategies as 
well as organizational structures. Hedge funds are almost always structured differently 
and should be evaluated based on intended structure and strategy. One feature that makes 
hedge funds more desirable to investors is the ability to "short" stocks with fewer re-
strictions than other fund verticals. "Shorting" in a clear sense is betting on a decrease in 
value of a particular asset or asset class. It is worth mentioning that while hedge funds 
have more complex capabilities, they do pose an elevated risk to less experienced 
investors. This is why the SEC has limited the solicitation of investors to "Institutional 
investors" and "accredited” investors with a net worth of over 1M USD or annual income 
of 200k USD or higher.  
 
The hedge fund fee structure is one of the core motivations that entice top money manag-
ers to launch their hedge funds. Hedge funds charge management fees usually ranging 
between one and two percent of the assets being managed. However, this rate is not fixed 
and can be higher depending on the track record of the manager.  
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The fees are calculated and paid as per the agreed upon terms either on a monthly or a 
quarterly basis. Additionally, Investors may pay performance fees that typically reach 
twenty percent of yearly net profits, based on the fund managers’ performance. These 
fees are in place to incentivize the fund manager to perform and produce outstanding 
results. This is separate from management fees which are paid to cover a manager’s op-
erating costs. Despite the high fees associated with investing in hedge funds, they do 
provide a substantial platform that allows investors to diversify and significantly reduce 
their overall risks thereby balancing the tradeoff (Hedge Fund Basics - Managed Funds 
Association, 2017). 
 
The General/ Limited partnership is the most common structure for hedge funds. In such 
a structure, the general partner reserves right to decide how the fund will operate. The 
limited partners can invest in the partnership and are only responsible for their expendi-
ture. The basic rule governing this structure is that there must be at least one general 
partner and one limited partner (Liu and Mello, 2011). Additionally, there can be more 
than one general partner and multiple limited partners. However, the Securities and Ex-
change Commission (SEC) regulation limits the number of investors to ninety-nine to 
qualify for SEC registration.  The following figure is an illustration of the structure typi-
cally outlined in a Hedge Fund General Limited partnership. 
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Figure 4: Structure of a Hedge fund partnership. (Mwellp.com, 2017) 
 
 Hedge Fund Corporate Governance 
Corporate governance refers to the prearrangement of rules, practices, and procedures 
that govern how hedge funds are managed and controlled. It tends to be aimed at balanc-
ing the interests of the numerous parties involved. This includes the shareholders, cus-
tomers, suppliers, sponsors and the government. Hence corporate governance rules pro-
vide a roadmap within which the company will be able to achieve its targets and monitor 
internal controls, performance evaluations and corporate disclosure (Kahan and Rock, 
2007). In recent years, there has been a growing concern on how hedge funds are 
governed. During the financial crisis of 2008, many investors became upset when hedge 
fund managers stopped them from withdrawing their funds and yet continued charging 
them. 
 
This prompted the application of previous legislation sections aimed at increasing trans-
parency and accountability from fund managers. Hedge funds are exempt from many 
regulations. However, certain sections in the acts of 1933 & 1934 still apply to hedge 
funds. Other provisions regulate fund managers and their advisers by creating limits to 
the number and type of investors as well as barring public solicitation (Kaal and Oesterle, 
2016). These acts contain anti-fraud rules and restrictions intended to protect investors 
from fraudulent practices. In recent years, the SEC has begun requiring hedge fund ad-
visers who manage more than $25 million and with over fourteen investors to register 
under the Investment Advisers Act (Kahan and Rock, 2007). In addition to this, hedge 
fund managers who are managing more than $150 million worth of assets are mandated 
to compile and submit detailed financial reports. 
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 Healthcare Funding Overview and Challenges 
When it comes to funding successful healthcare initiatives, it is necessary to identify 
where there are gaps and risks in the ecosystem. Typically, larger more established com-
panies are less of a risk to investors than smaller firms. New and innovative healthcare 
companies are racing to produce results that improve value for purchasers. Major leaps 
in health are being made due to the rapid progression of technology; biotechnology firms 
are seeing a substantial increase in venture capital resources being invested into their so-
lutions. The success of a biotechnology company, as well as others in healthcare, is highly 
dependent on a multitude of factors including having an adequate and promising pipeline 
of new medicines and or solutions. There are high risks associated with biotechnology 
firms in that their progression faces increasingly costly challenges when looking to pro-
duce usable solutions. This is one example of the numerous barriers currently facing the 
healthcare sector.  
 
One of the major difficulties in bringing medical solutions to market is the cost associated 
with FDA approval of a prescription drug. The cost of bringing a prescription drug to 
market is at a staggering all-time high and can cost an estimated 2.6 billion USD (Mullin, 
2014). The price is due to the rigorous standards set in place by the FDA, and the costs 
associated with research and development required to meet the standards. The time it 
takes to bring a drug to market is on average more than ten years in length. A study 
published by the Tufts Center for the Study of Drug Development (CSDD) concluded 
that an estimated 312 million USD is spent on pre-approval development, and noted that 
the rising costs could be attributed to the complexity of undergoing the many phases of 
clinical trials (Mullin, 2014). Depicted in figure 5 is an illustration that shows the rise in 
costs associated developing a new drug over the past forty years. 
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Figure 5. Rising cost of developing a new drug: The cost of developing a new drug has 
skyrocketed since the 1970s.(Tufts Center for the Study of Drug Development) 
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In addition to the increasing costs and time needed for bringing a new drug to market, the 
pharmaceutical industry also faces high levels of risk due to failure in the clinical trials.  
Clinical trials are one of the major costs associated with drug development. Table 1 shows 
the average R&D costs related to clinical trials in their respective domains over the critical 
phases. 
The challenges that come with seeking FDA approval play a significant role in the 
difficulties that face healthcare. Due to nature and challenges that face new drug devel-
opment, the need for external funding is a constant one and is one that can significantly 
be reduced by an investment fund designed specifically to support the companies in-
volved in such initiatives. 
 
Existing literature supports the efficient use of vehicles funded by investment, and pro-
jects increased funding in the coming years. GIIN and J.P. Morgan published their 5th 
annual impact investor survey that provides a detailed overview of impact investments 
and performance. The study debated the two largest issues facing impact investments as 
"Lack of appropriate capital across the risk/return spectrum" and "Shortage of high-qual-
ity investment opportunities with a track record"(J.P. Morgan, 2015). The survey also 
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noted that the healthcare sector faced substantial difficulty attracting capital, and was said 
only to engage the investors with a deep commitment to impact. 
 
The survey reinforces that an investment company aiming to support healthcare progress 
should first prioritize the financial performance of its portfolio to attract larger volumes 
of capital. Promoting the increase of capital towards a fund that invests in healthcare 
companies would certainly increase the potential for positive impacts in the health sector. 
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4. CONCLUSION 
4.1 Viable Fund Components & Discussion  
The components and discussion portion of this thesis are intended to deliver the prescrip-
tion that constitutes the chosen viable funding model. This section of the thesis contains 
the bulk of what was found throughout the investigation and is considered to fulfill the 
research aim as well as answer the research questions. The research findings that make a 
case for a viable fund strategy are systematically outlined and discussed throughout this 
chapter. The components are prefaced with a brief description so that the reader may 
understand the relevance and context. Following the preface, an assertion by the author 
can be found regarding the chosen methodology. The assertion is accompanied by a brief 
explanation of how it supports the research objectives and answers the research questions. 
  
Proposing a viable funding strategy includes attending to several different components 
that span across several spectrums. With all the relevant aspects considered by the author, 
the preferred fund vertical is appropriately one that can accommodate the undertaking of 
multiple strategies at different points in time so that the research objectives are preserved. 
This means that the portfolio and strategy of the fund will evolve naturally with the mat-
uration of the markets, companies, and the fund itself. The research came to understand 
the importance of establishing focus points throughout the lifecycle of the fund. That for 
example the early stage of the said fund is one who's initial focus is on attracting the most 
capital possible by investing in companies with relatively short development cycles (1-3 
years) likely to produce lucrative products or services that can either be acquired or 
brought to market. An example of the ideal partner would be A biotech company that 
produces a product or service that allows people to consume health care solutions similar 
to how they consume traditional goods and services. The evidence suggests that the com-
panies ripest for this type of investment are venture-backed firms that improve the deliv-
ery and or convenience of medical solutions. Venture Capital firms often take these com-
panies public and use IPO'S as an exit strategy when the company has reached a certain 
maturation point, making it a viable opportunity for mutual funds to step in. 
  
Discussion of the elements that make up the viable fund model can be found in the fol-
lowing components:  
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Fund type: The fund type refers to the kind of investment vehicle chosen to undertake 
investments so that the investment objectives outlined by the founders are unencumbered 
when carried out by the fund manager. The selected fund type is an open-ended mutual 
fund that invests in equity stocks. An open-ended mutual fund was chosen due to the 
customizable structure for sector specific investments, and minimal regulatory limitation 
on investment solicitation when compared the likes of hedge funds. The open-ended mu-
tual fund is the brand of an investment fund that is most suitable for a sector whose de-
velopment is subject to political and regulatory affairs with partial dependence to other 
sectors. The mutual fund was also the fund type of choice given their ability to support 
small to large cap companies during different critical stages of development without lim-
iting investor participation.  
  
Investment Objectives: The desired outcome from undertaking investment is considered 
the investment objective. The chosen targets for this fund are capital appreciation and 
Income from equities. The primary objective is to attain appreciation in the value of de-
ployed capital. The objective secondary to the first is to produce equity income. 
  
Portfolio Composition: The composition of a portfolio Includes the class of assets to be 
invested in, as well as the sector of focus for directing capital. The portfolio can be seen 
as an echo of the underlying investment strategy which in this particular case is 
predicated on the inclusion of companies most likely to enhance the lifespan of its inves-
tors. The adoption criteria by which the portfolio is populated is outlined in the strategic 
investment policy.  
  
Strategic investment policy: The policies behind the investment strategy include the rules 
and behaviors by which the fund engages with investments in general. The investment 
policy specifies the allocation and direction of investment resources across the board. The 
chosen policy behind the investment strategy is one that directs 80% of its capital towards 
the equity securities of listed companies whose primary focus is in the engagement of 
manufacturing, distribution, creation, research and development of biotechnological 
products, services, and or includes the acquisition of strong intellectual property. In addi-
tion to the inclusion of companies who focus on these objectives are; companies that di-
rectly or indirectly benefit from advances made in technology, changes in the political 
26 
landscape, and other factors that further stimulate the cycle of progress in healthcare. 
These companies roughly account for the remaining 20% of capital deployment.  
 
The fund's allocation of resources is, however, subject to minor deviations at the discre-
tion of the fund manager. One of the external elements that have influenced the scope of 
the strategic investment policy is the current political environment. Under the 2017 U.S. 
political landscape, investments in healthcare are likely to improve namely as a result of 
decreasing in business tax rates alongside the anticipation of more relaxed federal drug 
administration regulations on healthcare companies. A lower tax burden on healthcare 
companies should subsequently increase profits and reduce barriers to producing results. 
The reductions above would make it much easier for the participants involved to capture 
the value of research and development efforts.  
 
Investment approach: The investment approach pertains to the style of investing being 
used by the fund manager. Growth and Value are the two main styles a fund manager 
may incorporate into the general strategy. Growth investing seeks to direct capital to com-
panies with a strong proclivity towards monetary growth, justified by either a proven track 
record or by the potential to achieve high earnings growth. Value investing, on the other 
hand, tends to invest at a discounted rate towards undervalued companies on the stock 
market that possess strong qualities that have lasting value.  
 
The chosen investment approach recommends that the approach should be a blend of both 
value and growth investing. The reason behind the blended investment approach is to 
accommodate for how advancements are made in healthcare, the role the current political/ 
regulatory landscape plays, and how the approach may elicit participation from investors 
of all kinds. To support healthcare firms of all types, the approach should not be limited 
to one style. Investments towards growth are appropriate in accommodating the initial 
considerations mentioned above. Additionally, the use of the growth supports the key 
fund objective of attracting the most capital. The value approach is also used because it 
can enable the manager to operate within a margin of safety by investing in firms with 
fundamentally sound characteristics at a reasonably discounted price.   
  
Risk Approach: Managing risks associated with investment undertaking requires a sys-
tematic approach that addresses inherent risks as well as the sector and asset class specific 
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risks. The inherent risk profiles that require vigilance include overall volatility across the 
stock markets in response to adverse events that take place across economic, political, 
regulatory, and market spheres both foreign and domestic. Risks associated specifically 
with biotechnology and healthcare include inconsistent revenue patterns due to the high 
costs related to producing medical solutions. Mitigating risk in the health sector prompts 
the consideration of additional distinct elements and factors including patents, obsoles-
cence, rapid changes in technology, and unexpected changes in governmental regulation, 
fierce competition, intellectual property contention, and clinical trial failures. To reduce 
investor exposure to risk, the fund manager should take pre-emptive measures that ensure 
consistent performance.  
 
The risk policy of this fund should be highly considerate of the previously mentioned 
factors should they pose a threat. Momentary deviancies from normal investment activity 
are permitted if needed provided that they maintain alignment with the fund objective.  
 
Fund Structure: The fund structure can be seen as the macro intellectual framework that 
influences the context by which decisions are made. The purpose of the selected open-
ended mutual fund is to prioritize long-term capital appreciation while minimizing expo-
sure to risk. Secondarily, the subjective goal of the fund is to support and include compa-
nies that are: likely to produce usable solutions, indicate undercapitalized opportunities, 
and operate in good faith towards healthcare. A successful fund manager should be able 
to detect positive patterns and anomalies in the market and to adjust his or her position 
accordingly without deviating away from the fund objectives. The nature of undertaking 
investments in the healthcare sector requires that a manager be acutely aware of the po-
tential effects that external forces may bring, and capitalize on them at the appropriate 
time. This involves mapping out the positive or negative possible effects of sudden dis-
ruptions in the environment. Fortunately enough, the healthcare sector is anticipating a 
significant reduction in pressure from external parties. Technological advances are expo-
nentially increasing the potential for medical breakthroughs across the world, and current 
U.S. regulatory/political affairs do not appear to pose an increase in burden to biotech 
firms.   
  
Most of the components discussed in this chapter are interrelated. However, the compo-
nents do not always share the same context, and this makes future adjustments to the 
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strategy more difficult. To meet the research objectives effectively, the components have 
been connected to the macro context by using a hybrid of three strategies. The resulting 
investment strategy is designed to support the amalgamation of multiple strategies, ob-
jectives, and priorities throughout time to meet the research aim. 
  
The chosen strategies to integrate are the "Buy and Hold strategy," the “Performance 
weighting strategy," and the "Market timing strategy." These strategies are used in a 
timely manner meant to coincide with the value and growth based approach outlined ear-
lier in the investment approach. The buy and hold strategy in conjunction with the per-
formance weighting strategy indicates a hybrid strategy meant to hold long-term positions 
on large cap biotechnology or pharmaceutical firms. The presupposition of the buying 
and holding strategy is predicated on the notion of continual market growth over time. 
The probability for growth in the long term is more likely than not, and so holding long 
term positions have a decent likelihood of earning stable returns. Performance weighting 
indicates that the profits from investment activity into large cap biotech firms is reinvested 
into another underperforming portfolio, this is called rebalancing. Using the first combi-
nation is to ensure stability within the fund as well as to direct long-term support in the 
healthcare sector.  
 
The amount invested in large cap firms proportionally correlates to the risk level associ-
ated with the second strategy, the “Market timing strategy" which is used to invest small 
cap companies in various subsectors within the healthcare industry. The market timing 
strategy is a permutation of the value investment approach in that it is used to invest in 
smaller high-potential companies that are undervalued or with low market valuations 
when compared to the gross national product thereby indicating higher long-term returns 
and satisfying investment objectives. The market timing strategy is not based on the best 
time to invest in the entire market, but rather it has been modified by the author to com-
municate its utility towards the optimal time to invest based on valuation also known as 
valuation timing. 
  
While acknowledging the limitations of this study, the research regarding funding types 
was restricted to mutual and hedge funds. Publicly listed healthcare companies were in-
cluded in the study while privately held healthcare companies were not. It would be in-
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sightful to research the differences in strengths and weaknesses between public and pri-
vate healthcare firms. Also, if the research were to continue; it would explore the rela-
tionship between healthcare advancement and the funding of medical research in greater 
detail. 
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